PUBLIC COMPANY
save$ACADACADIA PHARMACEUTICALS INC
$ACAD18.67-0.43%San Diego, CA, USupdated 14h ago
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
community read0 votes
pipeline
5
marketed
2
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 32Marketed2Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- phase3Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
- phase2Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
- phase3Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
- phase2ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- phase3OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis
- phase3Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
🐶 Hiring Signal
News
- Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.biospace · 1d ago
- Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapyAs both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is hopeful of seeing a therapy that can truly change the disease's path.biospace · 22d ago
- Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s dataNovo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.biopharma_dive · 1mo ago
- Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experim…endpoints · 1mo ago
- Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forwardWhile Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy bod…biospace · 1mo ago
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…fiercebiotech · 1mo ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 2mo ago
- On second try, Acadia drug gets nod from European regulatorsThe influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.biopharma_dive · 4mo ago
- Celiac disease is entering a new era of therapeutic innovationFor the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.biopharma_dive · 5mo ago
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.biopharma_dive · 5mo ago
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that